On May 11, 2023 Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023 (Press release, Protagonist, MAY 11, 2023, View Source [SID1234631610]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Title: Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patients
Abstract Code: P1016
Presenting Author: Andrew Kuykendall, M.D., Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center
Session Date and Time: Friday, June 9, 18:00-19:00 CEST

Title: Pharmacokinetic and pharmacodynamic effects of rusfertide in polycythemia vera: Results from an ongoing Phase 2 study in patients with elevated hematocrit values
Abstract Code: P1048
Presenting Author: Marina Kremyanskaya, M.D., Ph.D., Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Session Date and Time: Friday, June 9, 18:00-19:00 CEST

Full abstract information can be found on the EHA (Free EHA Whitepaper) 2023 Hybrid Congress website at View Source